Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Medical Strategy GmbH
BioCentury | Jan 9, 2021
Finance
Targeted oncology is having a moment, again
Buysiders view 2021 as a window of opportunity for investing in targeted cancer drugs
BioCentury | Jan 13, 2020
Company News
MorphoSys nets $900M up front in global deal with Incyte for anti-CD19 mAb
BioCentury | Jan 11, 2020
Finance
Why buysiders say 2020 could be the year of the CNS
Neurology is back, as buysiders home in on 2020 opportunities
BioCentury | Jan 4, 2020
Finance
Politics aside, 2020 could be a good year for bringing back generalists
An appetite for risk has plenty of investors considering biotech again in 2020. What elections?
BioCentury | Jan 1, 2020
Financial News
Fourth quarter rally pushes biotech to strong finish
Five 4Q takeouts above $1B in upfront value, data readouts buoy biotech indexes in 2019
BioCentury | Apr 7, 2017
Finance
To market, to market
Investors watching for new approvals and cancer, Orphan data in 2Q17
BioCentury | Jan 6, 2017
Finance
Good riddance
Why investors think 2017 will be an up year for biotech despite macro uncertainty
BioCentury | Dec 31, 2016
Finance
Delivering takeouts
25th annual Buyside View sees investors eyeing mid-cap M&A targets in 2017
BioCentury | Jan 11, 2016
Finance
Sowing season
Buysiders eyeing big cap clinical milestones in 2016 to seed next growth spurt
BioCentury | Jan 14, 2013
Finance
Darwin's delight
2013 biotech stocks: Healthy balance sheets to support small cap tier-jumpers
Items per page:
1 - 10 of 11